No significant adverse reactions were observed, suggesting that combined Raf and Mek inhibition by SFN and AZD6244 at concentrations sufficient to achieve inhibition of tumor growth in vivo may be well tolerated. The gene discussed is MAP2K7; the disease is neoplasm.